PUBLISHER: The Business Research Company | PRODUCT CODE: 1691964
PUBLISHER: The Business Research Company | PRODUCT CODE: 1691964
Interstitial lung disease (ILD) refers to a group of lung conditions that affect the interstitium, the tissue and space surrounding the alveoli in the lungs. The interstitium is crucial for maintaining the structural integrity and function of the lungs, facilitating the exchange of gases between the lungs and the bloodstream.
The primary types of drugs used in the treatment of interstitial lung disease include oral corticosteroids, immunosuppressive medications, anti-fibrotic drugs, and others. Interstitial pneumonia, also referred to as non-infectious interstitial pneumonia, is a specific type of interstitial lung disease (ILD) that affects the interstitium, the tissue supporting the air sacs (alveoli) in the lungs. These drugs are indicated for the treatment of various ILD conditions, including interstitial pneumonia, idiopathic pulmonary fibrosis, nonspecific interstitial pneumonitis, hypersensitivity pneumonitis, cryptogenic organizing pneumonia (COP), sarcoidosis, and acute interstitial pneumonitis in both adults and children. They are distributed through a range of channels, including hospital pharmacies, retail pharmacies, and online pharmacies.
The interstitial lung disease market research report is one of a series of new reports from The Business Research Company that provides interstitial lung disease market statistics, including interstitial lung disease industry global market size, regional shares, competitors with an interstitial lung disease market share, detailed interstitial lung disease market segments, market trends and opportunities and any further data you may need to thrive in the interstitial lung disease industry. This interstitial lung disease market research report delivers a complete perspective on everything you need, with an in-depth analysis of the current and future scenarios of the industry.
The interstitial lung disease market size has grown strongly in recent years. It will grow from $1.97 billion in 2024 to $2.11 billion in 2025 at a compound annual growth rate (CAGR) of 7.2%. The growth in the historic period can be attributed to awareness and diagnosis improvement, immune system modulation therapies, respiratory rehabilitation programs, multidisciplinary care teams.
The interstitial lung disease market size is expected to see strong growth in the next few years. It will grow to $2.85 billion in 2029 at a compound annual growth rate (CAGR) of 7.9%. The growth in the forecast period can be attributed to precision medicine, novel drug development, regenerative medicine, telehealth and remote monitoring. Major trends in the forecast period include advancements in imaging technology, ai in imaging, fibrosis subtype differentiation, supportive care services.
The increasing prevalence of allergic conditions is expected to drive the growth of the interstitial lung disease (ILD) market in the future. An allergic condition occurs when the immune system overreacts to a substance, known as an allergen, that is typically harmless. Such allergic reactions can lead to ILD, specifically hypersensitivity pneumonitis, where an allergic response causes inflammation in the lungs. For example, in November 2023, the National Asthma Council, an Australia-based organization focused on asthma care, reported 467 asthma-related deaths in 2022, which included 299 females and 168 males. This represents an increase from 355 deaths in 2021. The rise in allergic diseases is contributing to the growth of the interstitial lung disease market. Therefore, the growing prevalence of allergic conditions is accelerating the expansion of the ILD market.
The rising incidence of autoimmune disorders is anticipated to fuel the growth of the interstitial lung disease market in the coming years. Autoimmune disorders occur when the immune system mistakenly attacks the body's healthy tissues and cells. The increasing number of autoimmune conditions is contributing to the growth of the ILD market by boosting demand for ILD-related healthcare services, advancing research and development, and driving improvements in treatments and patient care. For example, in September 2023, the Institute for Health Metrics and Evaluation, a US-based global health research organization, projected that global cases of rheumatoid arthritis will rise to 31.7 million by 2050, reflecting a significant increase over this period. As a result, the rising incidence of autoimmune diseases is propelling the growth of the interstitial lung disease market.
Leading companies in the interstitial lung disease market are focusing on trends such as the introduction of innovative therapies for various conditions, including idiopathic pulmonary fibrosis (IPF). IPF is a chronic and progressive lung disease characterized by the scarring of lung tissue, which results in breathing difficulties and decreased oxygen exchange. For example, in February 2024, C.H. Boehringer Sohn AG & Co. KG, a biopharmaceutical company based in Germany, received FDA approval for its BI 1015550 therapy for the treatment of IPF. BI 1015550 is an investigational oral medication that targets and inhibits phosphodiesterase 4B (PDE4B), providing antifibrotic and anti-inflammatory effects designed to slow the decline in lung function in patients with IPF.
In June 2023, Merck & Co., a US-based pharmaceutical company, acquired Prometheus Biosciences Inc. for $10.3 billion. This strategic acquisition is aimed at strengthening Merck & Co.'s immunology drug pipeline as it faces the looming loss of exclusivity for some of its top-selling products in the coming years. Prometheus Biosciences Inc., a US-based biotechnology company, specializes in developing therapeutic and complementary diagnostic products for the management of immune-mediated disorders, including interstitial lung disease (ILD) associated with systemic sclerosis (SSc-ILD).
Major companies operating in the interstitial lung disease market are Roche Laboratories Inc., Merck & Co. Inc., Bayer AG, Novartis Pharmaceuticals Corporation, The Bristol-Myers Squibb Company, Amgen Inc., Boehringer Ingelheim, Siemens Healthineers, Koninklijke Philips N.V., Teva Pharmaceuticals USA Inc., AstraZeneca PLC, Horizon Pharma USA Inc., Genentech Inc., Amneal Pharmaceuticals LLC, Fujirebio Diagnostics Inc., Insmed Inc., VIDA Diagnostics Inc., EmphyCorp Inc., Verseau Therapeutics, Regend Therapeutics Co., LTT Bio-Pharma Co. Ltd., Galecto Biotech, Pulmatrix Inc., PureTech Health PLC, Pneuma Respiratory Inc., Bellerophon Therapeutics Inc., MediciNova Inc., Altavant Sciences Inc., Verona Pharma plc.
North America was the largest region in the interstitial lung disease market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in interstitial lung disease report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the interstitial lung disease market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The interstitial lung disease market consists of revenues earned by entities by providing services such as individualized treatment plans and comprehensive support, pulmonary rehabilitation and oxygen therapy. The market value includes the value of related goods sold by the service provider or included within the service offering. The interstitial lung disease market also includes sales of prednisone, mycophenolate, azathioprine and cyclophosphamide. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Interstitial Lung Disease Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on interstitial lung disease market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Where is the largest and fastest growing market for interstitial lung disease ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The interstitial lung disease market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.